dm+d

Unassigned

New Medicines

Advanced Parkinson's disease - continuous SC infusion formulation

Information

New formulation
Mitsubishi Tanabe
Mitsubishi Tanabe

Development and Regulatory status

Phase I Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

ND0612L (low-dose formulation) is added to optimized oral standard of care. ND0612H (high dose) is for patients with severe PD and may provide an alternative to current treatments requiring surgery such as deep brain stimulation and LD/CD Intestinal Gel.
The incidence of the disease rises steeply with age; from 17.4 in 100,000 person years between 50 and 59 years of age to 93.1 in 100,000 person years between 70 and 79 years. [3]
Advanced Parkinson's disease - continuous SC infusion formulation
Subcutaneous infusion